A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
Active, not recruiting · Phase 3 · NCT03873402
Conditions: Renal Cell Carcinoma
At a glance
- Research payments reported, 2025
- $71,675
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 437
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- Nivolumab (biological), Ipilimumab (biological), Ipilimumab placebo (other)
- Dates
- Started 2019-06-21; completion 2027-03-11
- Results posted
- Not yet
The purpose of this study is to test the effectiveness and safety of nivolumab combined with ipilimumab compared to nivolumab monotherapy in participants with previously untreated kidney cancer that has spread.
From ClinicalTrials.gov, last updated 2026-01-21. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $71,675 in research payments for this study in 2025 (5 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- George R. Oliveira, M.D. Interventional Radiology · Miami, FL
- Subba R. Digumarthy, MD Radiology · Boston, MA
- Rajan Agarwal, MD Radiology · Abington, PA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $26,545
- Massachusetts General Physicians Organization $20,020
- Ggs Diagnostics Llc $18,090
- Global Radiology Associates PC $7,020
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.